Evidence map›Paper›PMID 32204629›Full record

ReviewImmunological investigations2020

Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles.

Fiona Y Glassman, Robert Dingman, Helena C Yau, Sathy V Balu-Iyer

Open access · greenAbstract readReview
In one paragraph

Review in Immunological investigations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. [Applications of novel biomaterials in the research and treatment of allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Fiona Y GlassmanDepartment of Pharmaceutical Sciences, University at Buffalo, the State University of New York , Buffalo, New York, USA.
Robert DingmanDepartment of Pharmaceutical Sciences, University at Buffalo, the State University of New York , Buffalo, New York, USA.
Helena C YauDepartment of Film and Media Studies, Washington University in St. Louis , St. Louis, Missouri, USA.
Sathy V Balu-IyerDepartment of Pharmaceutical Sciences, University at Buffalo, the State University of New York , Buffalo, New York, USA.
University at Buffalo, State University of New York · USCSL (United States) · USWashington University in St. Louis · US

Funding

HL-Development and Pharmacology of novel lipidic rAHF and biotherapeuticsR01HL070227 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALU-IYER, SATHY VENKAT · 2002 to 2019
$5.0M
NHLBI NIH HHS R01 HL070227
6 · The paper itself

Abstract

Phosphatidylserine (PS) is a naturally occurring anionic phospholipid that is primarily located in the inner leaflet of eukaryotic cell membranes. The role of PS during apoptosis is one of the most studied biological functions of PS. Externalization of PS during apoptosis mediates an "eat me" signal for phagocytic uptake, leading to clearance of apoptotic cells and thus maintain self-tolerance by immunological ignorance. However, an emerging view is that PS exposure-mediated cellular uptake is not an immunologically silent event, but rather promoting an active tolerance towards self and foreign proteins. This biological property of PS has been exploited by parasites and viruses in order to evade immune surveillance of the host immune system. Further, this novel immune regulatory property of PS that results in tolerance induction can be harnessed for clinical applications, such as to treat autoimmune conditions and to reduce immunogenicity of therapeutic proteins. This review attempts to provide an overview of the biological functions of PS in the immune response and its potential therapeutic applications.

Indexed as

ImmunotherapyNanoparticlesPhosphatidylserinesTheranostic NanomedicineAnimalsApoptosisDrug DesignDrug DevelopmentHumansMolecular StructurePhagocytesPhagocytosisPhosphatidylserinesApoptosisimmunogenicity MitigationimmunologyLipidsphospholipids/phosphatidylserinereceptors

Identifiers

PMID32204629
PMCPMC7508804
OpenAlexW3012927087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.